NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Cabergoline is an ergot-derivative dopamine agonist, widely used in the management of hyperprolactinemia and Parkinson's disease. However, its long-term use is associated with cardiac toxicity linked to its affinity for serotonin receptors present in valve tissue. This serotonin agonist activity can induce valvular heart disease, with a spectrum of severity ranging from mild involvement to severe hemodynamic compromise. We report a case of isolated mitral regurgitation in a 58-year-old male patient with a 12-year history of Parkinson's disease, presenting with inaugural acute decompensated heart failure in the context of previously unrecognized long-term cabergoline exposure. The toxicity manifested after a latency of nine years and significantly impacted quality of life. We additionally conducted a literature review to better elucidate the clinical manifestations, patient outcomes, and other molecules sharing a similar cardiotoxicity profile. This case underscores the need to consider drug-induced valvular heart disease in the differential diagnosis, especially in regions where rheumatic etiology dominates the clinical landscape. Baseline and follow-up echocardiographic evaluations in patients receiving long-term cabergoline therapy are essential for early detection and prevention of irreversible valvular damage.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.